Special Issue "The Mouse Xenograft Model in Cancer Research"
Deadline for manuscript submissions: 10 December 2023 | Viewed by 130
Interests: cancer research; anticancer drug development; mouse models of cancer; xenografts; cell culture; natural products; small molecules
Special Issues, Collections and Topics in MDPI journals
Human-to-mouse cancer xenografts are commonly used in cancer research to study the effectiveness of new treatments and to gain a better understanding of cancer biology.
Xenografts can be made from a wide range of human cancers, including breast, prostate, lung and colon cancers. They can also be used to study the effects of different cancer therapies, such as chemotherapy, radiotherapy and immunotherapy, in a living organism.
The use of human-to-mouse cancer xenografts has become a valuable tool in cancer research because it allows researchers to study human cancer in a living organism in a way that is not possible with cell cultures or other in vitro models.
However, there are limitations to this technique. These models cannot recapitulate the complex interactions between tumour cells, stroma and the human immune system. In addition, the use of animal models raises ethical concerns, and there is an ongoing debate about the validity of using animal models to study human diseases.
In this context, this Special Issue aims to bring the attention of Cancers readers to advances, cutting-edge developments, expertise and know-how across all cancer types in regard to these valuable animal models of cancer. Thus, we cordially invite authors to submit original articles, reviews and opinions that highlight their potential as tools for basic, translational and even precision medicine.
Dr. Konstantinos Dimas
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- patient-derived xenograft models
- humanised mice
- tumour biology
- tumour microenvironment
- novel anticancer therapies
- new biomarkers
- precision medicine
- gene therapy